The PPARgamma agonist pioglitazone modifies the vascular sodium-angiotensin II relationship in insulin-resistant rats.
Glitazones are efficient insulin sensitizers that blunt the effects of angiotensin II (ANG II) in the rat. Sodium chloride is another important modulator of the systemic and renal effects of ANG II. Whether glitazones interfere with the interaction between sodium and the response to ANG II is not known. Therefore, we investigated the effects of pioglitazone on the relationship between sodium and the systemic and renal effects of ANG II in rats. Pioglitazone, or vehicle, was administered for 4 wk to 8-wk-old obese Zucker rats. Animals were fed a normal-sodium (NS) or a high-sodium (HS) diet. Intravenous glucose tolerance tests, systemic and renal hemodynamic responses to ANG II, and the renal ANG II binding and expression of ANG II type 1 (AT(1)) receptors were measured. The results of our study were that food intake and body weight increased, whereas blood pressure, heart rate, filtration fraction, and insulin levels decreased significantly with pioglitazone in obese rats on both diets. Pioglitazone blunted the systemic response to ANG II and abolished the increased responsiveness to ANG II induced by a HS diet. Pioglitazone modified the renal hemodynamic response to changes in salt intake while maintaining a lower filtration fraction with ANG II perfusion. These effects were associated with a decrease in the number and expression of the AT(1) receptor in the kidney. In conclusion, these data demonstrate that the peroxisome proliferator-activated receptor-gamma agonist pioglitazone modifies the physiological relationship between sodium chloride and the response to ANG II in insulin-resistant rats.
Zanchi
Anne
A
Division of Nephrology, Dept. of Medicine, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland. azanchidel@hotmail.com
Perregaux
Christine
C
Maillard
Marc
M
Cefai
Daniel
D
Nussberger
Juerg
J
Burnier
Michel
M
D000804:Angiotensin II / Q000378:metabolism*; D000818:Animals; D001794:Blood Pressure / Q000502:physiology; D001808:Blood Vessels / Q000187:drug effects / Q000378:metabolism*; D001835:Body Weight / Q000502:physiology; D004032:Diet; D004305:Dose-Response Relationship, Drug; D004435:Eating / Q000502:physiology; D005951:Glucose Tolerance Test; D006339:Heart Rate / Q000502:physiology; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007333:Insulin Resistance / Q000502:physiology*; D008566:Membranes / Q000378:metabolism; D047495:PPAR gamma / Q000819:agonists*; D000077205:Pioglitazone; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D011924:Rats, Zucker; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism; D012079:Renal Circulation / Q000502:physiology; D012964:Sodium / Q000378:metabolism*; D012982:Sodium, Dietary / Q000494:pharmacology; D045162:Thiazolidinediones / Q000494:pharmacology*
D007004:Hypoglycemic Agents; D047495:PPAR gamma; D012333:RNA, Messenger; D044140:Receptor, Angiotensin, Type 1; D012982:Sodium, Dietary; D045162:Thiazolidinediones; D000804:Angiotensin II; D012964:Sodium; D000077205:Pioglitazone